Belite Bio Completes Last Subject Visit In Phase 3 DRAGON Clinical Trial Evaluating Tinlarebant For Treatment Of Stargardt Disease Type 1

Author: Benzinga Newsdesk | September 12, 2025 07:07am

• Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt disease
• Last subject visit completed in the pivotal Phase 3 DRAGON trial of Tinlarebant in Stargardt disease
• Topline data expected in Q4 2025

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt disease type 1 (STGD1).

Posted In: BLTE